• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用统一预处理方案进行第二次骨髓移植治疗恶性肿瘤复发的疗效

Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse.

作者信息

Chiang K Y, Weisdorf D J, Davies S M, Enright H, Kersey J H, McGlave P B, Miller W, Ramsay N K, Steinbuch M, Wagner J E, Blazar B R

机构信息

Department of Pediatrics and Medicine, University of Minnesota, Minneapolis 55455, USA.

出版信息

Bone Marrow Transplant. 1996 Jan;17(1):39-42.

PMID:8673052
Abstract

Twenty-three second bone marrow transplants (BMT) were performed between October 1987 and January 1994 for patients with malignant relapse following initial BMT. For first BMT, twenty-one of 23 (91%) were conditioned with cyclophosphamide plus total body irradiation. For second BMT, a uniform conditioning regimen consisting of busulfan and cyclophosphamide was used. Eleven patients had chronic myelogenous leukemia, seven acute leukemia, four lymphoma, and one myelodysplastic syndrome. Median patient age at second BMT was 32 years, the median time between first BMT and relapse was 22 months, and the median time to second BMT after relapse was 5 months. The second BMT marrow source included: autologous marrow (1), unrelated donors (4), new matched sibling donors (5) and same matched sibling donors as the first BMT (13). The Kaplan-Meier disease-free survival and survival rates at 3 years were 38 and 43%, respectively (median follow-up of survivors was 45 and 48 months, respectively), and five patients survive disease-free at 4-6 years. Nine of the 13 deaths occurred within 100 days after second BMT; eight had relapsed within 1 year of the first BMT. We conclude that: (1) second BMT can offer durable long-term survival in certain patients, especially those who relapse late after first transplant; (2) busulfan and cyclophosphamide is a suitable conditioning regimen for second BMT.

摘要

1987年10月至1994年1月期间,对初次骨髓移植(BMT)后恶性复发的患者进行了23例二次骨髓移植。初次BMT时,23例中有21例(91%)采用环磷酰胺加全身照射进行预处理。二次BMT时,采用白消安和环磷酰胺组成的统一预处理方案。11例患者患有慢性粒细胞白血病,7例患有急性白血病,4例患有淋巴瘤,1例患有骨髓增生异常综合征。二次BMT时患者的中位年龄为32岁,初次BMT与复发之间的中位时间为22个月,复发后至二次BMT的中位时间为5个月。二次BMT的骨髓来源包括:自体骨髓(1例)、无关供者(4例)、新的匹配同胞供者(5例)和与初次BMT相同的匹配同胞供者(13例)。3年时的无病生存率和总生存率分别为38%和43%(幸存者的中位随访时间分别为45个月和48个月),5例患者在4至6年时无病存活。13例死亡患者中有9例在二次BMT后100天内死亡;8例在初次BMT后1年内复发。我们得出以下结论:(1)二次BMT可以使某些患者获得持久的长期生存,尤其是那些初次移植后复发较晚的患者;(2)白消安和环磷酰胺是二次BMT合适的预处理方案。

相似文献

1
Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse.采用统一预处理方案进行第二次骨髓移植治疗恶性肿瘤复发的疗效
Bone Marrow Transplant. 1996 Jan;17(1):39-42.
2
Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.采用大剂量白消安和环磷酰胺(BU-CY)作为预处理方案进行无关供者异基因骨髓移植。
Bone Marrow Transplant. 1996 May;17(5):685-9.
3
Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy.骨髓移植后白血病复发:第二次清髓性治疗的效果
Bone Marrow Transplant. 1992 Mar;9(3):205-9.
4
Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.接受环磷酰胺-全身照射及环孢素治疗后首次完全缓解的急性髓系白血病患者接受异基因骨髓移植的长期随访
Bone Marrow Transplant. 1996 Oct;18(4):741-6.
5
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.对于高危或晚期血液系统恶性肿瘤患者,采用分次全身照射、依托泊苷和环磷酰胺治疗,随后进行异基因骨髓移植。
Biol Blood Marrow Transplant. 1997 Dec;3(6):324-30.
6
Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.急性白血病患儿的异基因骨髓移植:接受大剂量阿糖胞苷和分次全身照射预处理患者的长期随访
Bone Marrow Transplant. 1997 Jul;20(1):5-10. doi: 10.1038/sj.bmt.1700827.
7
Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.费城染色体阳性急性淋巴细胞白血病骨髓移植中的强化预处理方案
Bone Marrow Transplant. 1998 Dec;22(11):1029-33. doi: 10.1038/sj.bmt.1701498.
8
Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.环磷酰胺、阿糖胞苷和全身照射作为白血病患者异基因骨髓移植的预处理方案。
Bone Marrow Transplant. 1999 Jun;23(11):1095-100. doi: 10.1038/sj.bmt.1701786.
9
CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.来自基因分型 HLA 不相同的相关供体的 CD6+ T 细胞耗竭的异基因骨髓移植。
Biol Blood Marrow Transplant. 1997 Apr;3(1):11-7.
10
Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.急性白血病患者的异基因匹配去T细胞骨髓移植
Cancer J Sci Am. 1996 Nov-Dec;2(6):330-4.

引用本文的文献

1
[Efficacy and safety of secondary allogeneic hematopoietic stem cell transplantation in 70 patients with recurrent hematologic malignancies after transplantation].70例移植后复发性血液系统恶性肿瘤患者二次异基因造血干细胞移植的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):458-464. doi: 10.3760/cma.j.issn.0253-2727.2023.06.003.
2
The role of second transplants for leukemia.二次移植在白血病治疗中的作用。
Best Pract Res Clin Haematol. 2016 Dec;29(4):359-364. doi: 10.1016/j.beha.2016.10.011. Epub 2016 Oct 19.
3
Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
异基因造血干细胞移植后急性髓系白血病复发的治疗
Curr Hematol Malig Rep. 2014 Jun;9(2):186-92. doi: 10.1007/s11899-014-0209-2.
4
Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.自体移植治疗急性髓系白血病失败后行无关供者异基因移植:来自国际血液和骨髓移植研究中心的研究。
Biol Blood Marrow Transplant. 2013 Jul;19(7):1102-8. doi: 10.1016/j.bbmt.2013.04.022. Epub 2013 Apr 28.
5
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).自体移植后复发的血液系统恶性肿瘤患者的低强度预处理异基因造血细胞移植:来自癌症和白血病组 B(CALGB 试验 100002)的多机构前瞻性研究。
Biol Blood Marrow Transplant. 2011 Apr;17(4):558-65. doi: 10.1016/j.bbmt.2010.07.015. Epub 2010 Jul 30.
6
Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t(8;21) and CD56-positivity.患者存在染色体异常 t(8;21)和 CD56 阳性,异基因造血干细胞移植后发生急性髓系白血病复发性髓外复发。
Int J Hematol. 2009 Oct;90(3):374-377. doi: 10.1007/s12185-009-0385-3. Epub 2009 Jul 24.
7
Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant.自体移植后复发的霍奇金病和非霍奇金淋巴瘤患者的治疗选择。
Curr Treat Options Oncol. 2005 Jul;6(4):279-87. doi: 10.1007/s11864-005-0032-z.
8
Second allogeneic hematopoietic stem cell transplantation for leukemia relapse after first allogeneic transplantation: outcome of 16 patients in a single institution.首次异基因造血干细胞移植后白血病复发的二次异基因造血干细胞移植:单中心16例患者的结局
Int J Hematol. 2002 Apr;75(3):318-23. doi: 10.1007/BF02982050.
9
Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation.采用基于氟达拉滨的低强度预处理方案进行第二次异基因外周血干细胞移植治疗异基因骨髓移植后复发的骨髓增生异常综合征
Int J Hematol. 2001 Jan;73(1):122-5. doi: 10.1007/BF02981914.